Bioequivalence of fixed-dose combination Myrin®-P Forte and reference drugs in loose combination

BACKGROUND: Myrin®-P Forte is a fixed-dose combination (FDC) tablet containing rifampicin (RMP, 150 mg), isoniazid (INH, 75 mg), ethambutol (EMB) hydrochloride (275 mg) and pyrazinamide (PZA, 400 mg) developed for the treatment of tuberculosis (TB).SETTING: This study was conducted at a single centr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The international journal of tuberculosis and lung disease 2013-12, Vol.17 (12), p.1596-1601
Hauptverfasser:	Wang, H. F., Wang, R., O'Gorman, M., Crownover, P., Naqvi, A., Jafri, I.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Anti-Tuberculosis Antitubercular Agents - administration & dosage Antitubercular Agents - adverse effects Antitubercular Agents - blood Antitubercular Agents - pharmacokinetics Area Under Curve Bacterial diseases Biological and medical sciences Cross-Over Studies Drug Combinations Drug Therapy, Combination Ethambutol Ethambutol - administration & dosage Ethambutol - adverse effects Ethambutol - blood Ethambutol - pharmacokinetics Fasting - blood Female Healthy Volunteers Human bacterial diseases Humans Infectious diseases isoniazid Isoniazid - administration & dosage Isoniazid - adverse effects Isoniazid - blood Isoniazid - pharmacokinetics Male Medical sciences Middle Aged Pneumology Pyrazinamide Pyrazinamide - administration & dosage Pyrazinamide - adverse effects Pyrazinamide - blood Pyrazinamide - pharmacokinetics rifampicin Rifampin - administration & dosage Rifampin - adverse effects Rifampin - blood Rifampin - pharmacokinetics Singapore Therapeutic Equivalency Tuberculosis and atypical mycobacterial infections Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!